CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study — Stella

Home/T-lymphoblastic Lymphoma/

View on ClinicalTrials.gov

Recruiting

Back to T-lymphoblastic Lymphoma trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Shanghai Ruijin Hospital, Shanghai

Key details

Phase

Early testing

Sponsor

Hebei Senlang Biotechnology Inc., Ltd.

Enrollment target

~9 participants

Started

August 2023

Primary completion

August 2024

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 75 Years

Last updated November 2023

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.